> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 15 Observations in Qualgen FDA-483
- URL: https://www.fdaweb.com/15-observations-in-qualgen-fda-483/
- Published: 2022-05-05T12:00:00.000Z
- Updated: 2026-09-14T17:43:30.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151755

FDA has released the FDA-483 with 15 observations issued following a 4/29-6/15/21 inspection at Qualgen, an Edmond, OK, outsourcing facility. The observations were: 

- failing to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products and to have the responsibilities and procedures applicable to the quality control unit in writing or fully followed;
- procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, or followed;
- failing to have written methods of cleaning or methods of processing to remove pyrogenic properties;
- failing to establish and follow written procedures for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing, or holding of a drug product;
- failure of the quality control unit to review and approve changes to written procedures;
- clothing of personnel engaged in the manufacturing and processing of drug products is not appropriate for the duties they perform;
- laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that in-process materials and drug products conform to appropriate standards of identity, strength, and purity;
- separate or defined areas and control systems necessary to prevent contamination or mix-ups are deficient;
- equipment used in the manufacture, processing, packing, or holding of a drug product is not of appropriate design or suitably located to facilitate operations for its cleaning and maintenance;
- drug product closures were not clean and sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use;
- buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable size, construction, and location to facilitate cleaning, maintenance, and proper operation;
- routine calibration of automatic, mechanical, and electronic equipment is not performed according to a written program designed to assure proper performance;
- master production and control records are deficient in that they do not include complete manufacturing and control instructions and procedures;
- labels of the outsourcing facility’s drug products do not include information required by regulations; and
- the containers of the outsourcing facility’s drug products do not include information required by regulations.